Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Study of Sapanisertib in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers Including Pancreatic Cancer

Summary

The purpose of this phase I trial is to study the side effects and best dose of Sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back and have spread to another place in the body or cannot be removed by surgery. Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

General Information

NCT#: NCT02159989
Study ID: 2013-0665 NCI-2014-01107
Trial Phase: Phase I

Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Ziv-Aflibercept, Sapanisertib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search